OTCMKTS:GTBP - GT Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.33
  • Forecasted Upside: 254.31 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.15
▲ +0.15 (2.14%)

This chart shows the closing price for GTBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GT Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTBP

Analyst Price Target is $25.33
▲ +254.31% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GT Biopharma in the last 3 months. The average price target is $25.33, with a high forecast of $26.00 and a low forecast of $25.00. The average price target represents a 254.31% upside from the last price of $7.15.

This chart shows the closing price for GTBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in GT Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/14/2021HC WainwrightReiterated RatingBuy$25.00
6/28/2021HC WainwrightReiterated RatingBuy$25.00
6/24/2021B. RileyReiterated RatingBuy$21.00 ➝ $26.00
5/24/2021HC WainwrightInitiated CoverageBuy$25.00
4/13/2021B. RileyInitiated CoverageBuy$21.00
3/17/2021Roth CapitalInitiated CoverageBuy$25.00
(Data available from 9/28/2016 forward)

News Sentiment Rating

1.24 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
GT Biopharma logo
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product GTB-3550 is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Beverly Hills, CA.
Read More

Today's Range

Now: $7.15
Low: $6.82
High: $7.33

50 Day Range

MA: $9.21
Low: $7.00
High: $12.21

52 Week Range

Now: $7.15
Low: $2.55
High: $19.73

Volume

249,936 shs

Average Volume

430,237 shs

Market Capitalization

$151.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of GT Biopharma?

The following Wall Street sell-side analysts have issued reports on GT Biopharma in the last year: B. Riley, HC Wainwright, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for GTBP.

What is the current price target for GT Biopharma?

3 Wall Street analysts have set twelve-month price targets for GT Biopharma in the last year. Their average twelve-month price target is $25.33, suggesting a possible upside of 261.9%. B. Riley has the highest price target set, predicting GTBP will reach $26.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $25.00 for GT Biopharma in the next year.
View the latest price targets for GTBP.

What is the current consensus analyst rating for GT Biopharma?

GT Biopharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTBP will outperform the market and that investors should add to their positions of GT Biopharma.
View the latest ratings for GTBP.

How do I contact GT Biopharma's investor relations team?

GT Biopharma's physical mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company's listed phone number is (800) 304-9888 and its investor relations email address is [email protected] The official website for GT Biopharma is www.gtbiopharma.com.